1. Search Result
Search Result
Pathways Recommended: Membrane Transporter/Ion Channel
Results for "

voltage-gated calcium channel

" in MedChemExpress (MCE) Product Catalog:

35

Inhibitors & Agonists

2

Screening Libraries

1

Fluorescent Dye

2

Biochemical Assay Reagents

8

Peptides

3

Natural
Products

1

Recombinant Proteins

3

Isotope-Labeled Compounds

2

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-156664

    Calcium Channel Neurological Disease
    Calcium Channel antagonist 3 (compound 397) is an inhibitor of voltage-gated calcium channels with an IC50 value of 5-20μM .
    Calcium Channel antagonist 3
  • HY-156669

    Calcium Channel Neurological Disease
    Calcium Channel antagonist 4 (compound 189) is an inhibitor of voltage-gated calcium channels with an IC50 value of 5-20μM .
    Calcium Channel antagonist 4
  • HY-169845

    Calcium Channel Neurological Disease
    Calcium Channel antagonist 6 (Compound 328) is a highly selective antagonist of voltage-gated calcium channel CaV2.2 with an IC50 value of 0.37 μM. Calcium Channel antagonist 6 inhibits of neuron depolarization-induced Ca 2+ influx. Calcium Channel antagonist 6 is promising for research of neuropathic pain .
    Calcium Channel antagonist 6
  • HY-148866

    Calcium Channel Neurological Disease Endocrinology
    Cavα2δ1&NET-IN-3 (example 216) is an inhibitor of the subunit α2δ of voltage-gated calcium channels (VGCC) and noradrenaline transporter (NET). Cavα2δ1&NET-IN-3 has Kis of 100-500 nM for human α2δ-1 subunit of Cav2.2 calcium channel and NET, respectively .
    Cavα2δ1&NET-IN-3
  • HY-142240

    HSK16149

    Calcium Channel Neurological Disease
    Crisugabalin (HSK16149) is a novel ligand of voltage-gated calcium channel (VGCC) α 2 δ subunit.
    Crisugabalin
  • HY-170424

    Biochemical Assay Reagents Others
    D-myo-Inositol-1,3,4,5-tetrakisphosphate potassium increases the extracellular Ca 2+ entry through upregulation of voltage-gated calcium channels .
    D-myo-Inositol-1,3,4,5-tetrakisphosphate potassium
  • HY-P5142

    ω-ACTX-Hv1; ω-Atracotoxin-HV1

    Calcium Channel Neurological Disease
    ω-Hexatoxin-Hv1a is a neurotoxin that can be isolated from the venom spider (Hadronyche versuta).ω-Hexatoxin-Hv1a blocks voltage-gated calcium channels .
    ω-Hexatoxin-Hv1a
  • HY-P5179

    HWTX-I

    Calcium Channel Sodium Channel Neurological Disease
    Huwentoxin I (HWTX-I) is a peptide toxin that inhibits voltage-gated sodium channels and N-type calcium channels. Huwentoxin I inhibits sodium channels in rat hippocampus and cockroach dorsal unpaired median (DUM) neurons with IC50 values of 66.1 and 4.80 nM, respectively .
    Huwentoxin I
  • HY-148863

    Calcium Channel Monoamine Transporter Inflammation/Immunology
    Cavα2δ1&NET-IN-2 (Compound 45CS) is a dual inhibitor of the α2δ‑1 subunit of voltage-gated calcium channels (Cavα2δ-1) and the norepinephrine transporter (NET). Cavα2δ1&NET-IN-2 inhibits Cavα2δ-1 with a Ki of 454 nM. Cavα2δ1&NET-IN-2 inhibits NET with a Ki of 59 nM and IC50 of 7 nM. Cavα2δ1&NET-IN-2 can be used for research of pain .
    Cavα2δ1&NET-IN-2
  • HY-148862

    Calcium Channel Monoamine Transporter Inflammation/Immunology
    Cavα2δ1&NET-IN-1 (Compound 59S) is a dual inhibitor of the α2δ‑1 subunit of voltage-gated calcium channels (Cavα2δ-1) and the norepinephrine transporter (NET). Cavα2δ1&NET-IN-1 inhibits Cavα2δ-1 with a Ki of 112 nM. Cavα2δ1&NET-IN-1 inhibits NET with a Ki of 383 nM and IC50 of 67 nM. Cavα2δ1&NET-IN-1 can be used for research of pain .
    Cavα2δ1&NET-IN-1
  • HY-D2266

    Fluorescent Dye Neurological Disease
    FluoBar1 is an imaging fluorescence probe modified by a barbiturate ligand with fluorescent coumarin. FluoBar1 can monitor L-type voltage-gated calcium channels (LTCC) in living cells in real time for the study of neurological diseases .
    FluoBar1
  • HY-17402
    Nisoldipine
    1 Publications Verification

    BAY-k 5552

    Calcium Channel Reactive Oxygen Species (ROS) Infection Cardiovascular Disease Neurological Disease
    Nisoldipine (BAY-k 5552; Sular) is an orally active and blood-brain barrier-penetrating dihydropyridine calcium antagonist, with greater vascular selectivity than other calcium channel antagonists. Nisoldipine inhibits calcium influx and blocks voltage-gated calcium channels. Nisoldipine dilates coronary and systemic arteries. Nisoldipine has antihypertensive and anti-anginal activity. Nisoldipine also displays neuroprotective and antiviral activity .
    Nisoldipine
  • HY-Y0537E

    Biochemical Assay Reagents Potassium Channel Calcium Channel Neurological Disease
    Potassium chloride, for cell culture is potassium chloride that can be used for cell culture. Potassium chloride, for cell culture increases extracellular potassium ion concentration to induce cellular depolarization, thereby activating voltage-gated calcium channels and regulating intracellular calcium signaling. Potassium chloride, for cell culture upregulates Brn-5. Potassium chloride, for cell culture inhibits the proliferation of neurons and some plant cells .
    Potassium chloride, for cell culture
  • HY-106454

    Norfludiazepam

    Calcium Channel Neurological Disease
    N-Desalkylflurazepam (Norfludiazepam) is a long-acting metabolite of benzodiazepine compounds, such as Flurazepam. N-Desalkylflurazepam inhibits L-type voltage-gated calcium channels with IC50 values of 55 μM and 37 μM for Cav1.2 and Cav1.3, respectively .
    N-Desalkylflurazepam
  • HY-P2699

    GrTx; ω-GsTx SIA

    Calcium Channel Neurological Disease
    ω-Grammotoxin SIA (GrTx) is P/Q and N-type voltage-gated Calcium channels inhibitor. ω-Grammotoxin SIA is also a protein toxin that can be obtained from spider venom. ω-Grammotoxin SIA has the potential to study neurological diseases as well as cardiovascular diseases .
    ω-Grammotoxin SIA
  • HY-132932

    Calcium Channel Others
    Cavα2δ-IN-1 shows high selectivity for voltage-gated calcium channels Cavα2δ-1 (Ki 6 nM) versus Cavα2δ-2 (Ki > 10000 nM).
    Cavα2δ-IN-1
  • HY-N7503

    Histamine Receptor Calcium Channel Calmodulin Infection Metabolic Disease Cancer
    Psoralenoside is a benzofuran glycoside from Psoralea corylifolia . Psoralenoside exhibits high binding affinities against histaminergic H1, calmodulin, and voltage-gated L-type calcium channels (E-value≥-6.5 Kcal/mol) . Psoralenoside shows estrogen-like activity, osteoblastic proliferation accelerating activity, antitumor effects and antibacterial activity .
    Psoralenoside
  • HY-106454R

    Norfludiazepam (Standard)

    Reference Standards Calcium Channel Neurological Disease
    N-Desalkylflurazepam (Standard) is the analytical standard of N-Desalkylflurazepam. This product is intended for research and analytical applications. N-Desalkylflurazepam (Norfludiazepam) is a long-acting metabolite of benzodiazepine compounds, such as Flurazepam. N-Desalkylflurazepam inhibits L-type voltage-gated calcium channels with IC50 values of 55 μM and 37 μM for Cav1.2 and Cav1.3, respectively .
    N-Desalkylflurazepam (Standard)
  • HY-W701464

    Isotope-Labeled Compounds Others
    N-Desalkylflurazepam-d4 is a deuterated labeled N-Desalkylflurazepam (HY-106454). N-Desalkylflurazepam (Norfludiazepam) is a long-acting metabolite of benzodiazepine compounds, such as Flurazepam. N-Desalkylflurazepam inhibits L-type voltage-gated calcium channels with IC50 values of 55 μM and 37 μM for Cav1.2 and Cav1.3, respectively .
    N-Desalkylflurazepam-d4
  • HY-N6687R

    A-23187 (Standard); Antibiotic A-23187 (Standard)

    Oxidative Phosphorylation Reference Standards Bacterial Fungal Apoptosis Autophagy Antibiotic Infection Cancer
    N-Desalkylflurazepam (Standard) is the analytical standard of N-Desalkylflurazepam. This product is intended for research and analytical applications. N-Desalkylflurazepam (Norfludiazepam) is a long-acting metabolite of benzodiazepine compounds, such as Flurazepam. N-Desalkylflurazepam inhibits L-type voltage-gated calcium channels with IC50 values of 55 μM and 37 μM for Cav1.2 and Cav1.3, respectively .
    Calcimycin (Standard)
  • HY-106345

    FKBP Calcium Channel Neurological Disease Inflammation/Immunology
    ILS-920 is a nonimmunosuppressive Rapamycin analog with reduced immunosuppressive activity and potent neuroprotective activity. ILS-920 binds selectively to the immunophilin FKBP52 and to the β1-subunit of L-type voltage-gated calcium channels (VGCC). ILS-920 shows 200-fold selectivity for FKBP52 versus FKBP12 .
    ILS-920
  • HY-P1427A

    Potassium Channel Neurological Disease
    Guangxitoxin 1E TFA is the TFA salt form of Guangxitoxin 1E (HY-P1427). Guangxitoxin 1E TFA is a peptide toxin and a selective inhibitor for voltage-gated potassium channel KV2.1 and KV2.2 with IC50 of 1-3 nM. Guangxitoxin 1E TFA enhances glucose-stimulated intracellular calcium ion oscillations and increases insulin secretion in a glucose-dependent manner .
    Guangxitoxin 1E TFA
  • HY-Y1667
    2,6-Dibromophenol
    1 Publications Verification

    Calcium Channel Fungal Parasite Metabolic Disease
    2,6-Dibromophenol (2,6-DBP) is a weak inhibitor targeting voltage-gated Ca 2+ channels. 2,6-Dibromophenol has no significant effect on potassium-induced calcium elevation in PC12 cells. 2,6-Dibromophenol shows a 48 h EC50 of 2.78 mg/L for Daphnia magna and a 96 h EC50 of 9.90 mg/L for algae (Scenedesmus quadricauda) .
    2,6-Dibromophenol
  • HY-B0768A
    Lomerizine dihydrochloride
    1 Publications Verification

    KB-2796

    Calcium Channel Neurological Disease
    Lomerizine dihydrochloride is an antagonist of L- and T-type voltagegated calcium channels.
    Lomerizine dihydrochloride
  • HY-B0768

    KB-2796 free base

    Calcium Channel Neurological Disease
    Lomerizine is an antagonist of L- and T-type voltagegated calcium channels.
    Lomerizine
  • HY-108006
    Mirogabalin besylate
    5 Publications Verification

    DS 5565 besylate

    Calcium Channel Neurological Disease
    Mirogabalin besylate is a selective and orally available ligand for the α2δ subunit of voltage-gated calcium channels, with Kds of 13.5 nM, 22.7 nM, 27 nM, and 47.6 nM for human α2δ-1, human α2δ-2, rat α2δ-1, and rat α2δ-2, respectively.
    Mirogabalin besylate
  • HY-P1651

    TRP Channel Cancer
    SOR-C13, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 has anticancer activity .
    SOR-C13
  • HY-P1078

    Calcium Channel Neurological Disease
    Huwentoxin XVI, an analgesic, is a highly reversible and selective mammalian N-type calcium channel (IC50 of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .
    Huwentoxin XVI
  • HY-P1651A

    TRP Channel Cancer
    SOR-C13 TFA, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 TFA has anticancer activity .
    SOR-C13 TFA
  • HY-P1078A

    Calcium Channel Neurological Disease
    Huwentoxin XVI TFA, an analgesic, is a highly reversible and selective mammalian N-type calcium channel (IC50 of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI TFA has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .
    Huwentoxin XVI TFA
  • HY-B0768AR

    KB-2796 (Standard)

    Reference Standards Calcium Channel Neurological Disease
    Lomerizine dihydrochloride (Standard) is the analytical standard of Lomerizine dihydrochloride. This product is intended for research and analytical applications. Lomerizine dihydrochloride is an antagonist of L- and T-type voltagegated calcium channels.
    Lomerizine dihydrochloride (Standard)
  • HY-B0768S

    Calcium Channel Isotope-Labeled Compounds Neurological Disease
    Lomerizine-d4 is the deuterium labeled Lomerizine (HY-B0768). Lomerizine is an antagonist of L- and T-type voltagegated calcium channels .
    Lomerizine-d4
  • HY-111828
    TTA-A2
    1 Publications Verification

    Calcium Channel Neurological Disease
    TTA-A2 is a potent, selective and orally active t-type voltage gated calcium channel antagonist with reduced pregnane X receptor (PXR) activation. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy .
    TTA-A2
  • HY-132184

    5,6-EET; (±)5,6-EpETrE

    Adrenergic Receptor Calcium Channel Endocrinology
    5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC50=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2.
    5,6-Epoxyeicosatrienoic acid
  • HY-132184S

    5,6-EET-d11; (±)5,6-EpETrE-d11

    Isotope-Labeled Compounds Adrenergic Receptor Endocrinology
    5,6-Epoxyeicosatrienoic acid-d11 (5,6-EET-d11) is deuterium labeled 5,6-Epoxyeicosatrienoic acid. 5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC50=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2, as measured by oxygen consumption and product formation assays when used at a concentration of 50 μM. (±)5,6-Epoxyeicosatrienoic acid is provided as a mixture of the free acid and lactone .
    5,6-Epoxyeicosatrienoic acid-d11

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: